AVTR vs RGEN
AVTR: Global provider of mission-critical laboratory consumables, specialty chemicals, and biopharmaceutical manufacturing solutions serving life sciences, healthcare, and advanced technology markets worldwide. RGEN: Repligen provides critical, high-efficiency bioprocessing technologies and systems that enable biopharmaceutical companies to manufacture life-saving biological drugs.
Side-by-side fundamentals
| Metric | AVTR | RGEN | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $10.95 | $140.09 | |
| Market cap as of 2026-07-23 | $7.5B | $7.9B | |
| P/E as of 2026-07-23 | n/a | 153.85 | |
| PEG as of 2026-07-23 | n/a | 6.61 | |
| Net margin as of 2026-07-23 | -8.4% | +6.7% | RGEN higher |
| Gross margin as of 2026-07-23 | +32.1% | +53.1% | RGEN higher |
| Operating margin as of 2026-07-23 | -4.6% | +6.7% | RGEN higher |
| ROE as of 2026-07-23 | -9.6% | +2.5% | RGEN higher |
| ROA as of 2026-07-23 | -4.6% | +1.8% | RGEN higher |
| Debt / equity as of 2026-07-23 | 0.68 | 0.26 | RGEN lower |
| Revenue growth (YoY) as of 2026-07-23 | -2.0% | +18.2% | RGEN higher |
| Revenue CAGR (3y) SEC XBRL | -4.5% | +30.5% | RGEN higher |
| Beta as of 2026-07-23 | 0.92 | 1.03 | |
| 1-year return as of 2026-07-22 close | -10.9% | +22.8% | RGEN higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.